David Reardon, MD

Dana-Farber Cancer Institute: Harvard School Boston, MA
Clinical Director, Center for Neruo-Oncology

Dr. Reardon (Professor of Medicine, Harvard Medical School and Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute) completed his MD at Tufts Medical School, his Residency at Johns Hopkins (Pediatrics) and his fellowship at University of Michigan Hospital in Pediatric Hematology/Oncology. He is board certified in Neuro-Oncology and Pediatric Hematology/Oncology. In his current position, Dr. Reardon serves as a principal investigator for multiple clinical trials for primary brain tumors and collaborates heavily with the DFCI cancer immunology group. His laboratory work focuses on preclinical studies evaluating promising immune based therapies and combinatorial approaches in orthotopic, immunocompetent syngeneic glioblastoma models. Prior to joining the Dana-Farber in 2011, he served as Associate Deputy Director of the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke University where he oversaw clinical/translational research operations. His clinical and research efforts were recognized by receipt of the R. K Rundles Award for Excellence in Clinical Oncology Research in 2007 as well as the 2015 and 2016 Awards for Excellence in Clinical Research from the Society of Neuro-Oncology. His NCI grant awards include an R21 NIH and he currently co-leads a PO1 grant.

AR-67 has the potential to deliver the efficacy of Camptothecins with significantly less gastrointestinal and hematological toxicity than Irinotecan. That could be a game changer for patients with gastrointestinal cancers.
Dr. Gerard Blobe, MD, PhD.Duke University School of Medicine.
AR–67 is a next generation camptothecin optimized for fewer side effects and blood-brain-barrier penetration. In glioblastoma patients treated with AR-67 on a clinical trial at our center, we saw encouraging outcomes and tumor shrinkage. AR-67 was extremely well tolerated. I believe AR-67 represents a novel approach in treating this devastating disease.
Dr. Jai Grewal, MD.NSPC Brain and Spine Surgery, NY

References

1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980

2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.

3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680

4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)

5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997.  https://www.jbc.org

6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org